KR20020012567A - 1,5-벤조디아제핀 유도체 - Google Patents

1,5-벤조디아제핀 유도체 Download PDF

Info

Publication number: KR20020012567A
Authority: KR; South Korea
Prior art keywords: formula; compound; cck; enantiomer; phenyl
Prior art date: 1999-05-06
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Withdrawn

Application number

KR1020017014075A

Other languages

English (en)

Korean (ko)

Inventor

데이비드 콜클로우

앤 훗슨

저지 리스자드 츄히직

Original Assignee

그레이엄 브레레톤, 레슬리 에드워즈

글락소 그룹 리미티드

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1999-05-06

Filing date

2000-05-04

Publication date

2002-02-16

1999-05-06 Priority claimed from GBGB9910366.5A external-priority patent/GB9910366D0/en

2000-04-05 Priority claimed from GBGB0008179.4A external-priority patent/GB0008179D0/en

2000-05-04 Application filed by 그레이엄 브레레톤, 레슬리 에드워즈, 글락소 그룹 리미티드 filed Critical 그레이엄 브레레톤, 레슬리 에드워즈

2002-02-16 Publication of KR20020012567A publication Critical patent/KR20020012567A/ko

Status Withdrawn legal-status Critical Current

Links

ZVAPWJGRRUHKGP-UHFFFAOYSA-N 1h-1,5-benzodiazepine Chemical class N1C=CC=NC2=CC=CC=C12 ZVAPWJGRRUHKGP-UHFFFAOYSA-N 0.000 title description 2
150000001875 compounds Chemical class 0.000 claims abstract description 53
238000000034 method Methods 0.000 claims abstract description 19
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 15
201000010099 disease Diseases 0.000 claims abstract description 11
208000008589 Obesity Diseases 0.000 claims abstract description 8
230000001404 mediated effect Effects 0.000 claims abstract description 8
235000020824 obesity Nutrition 0.000 claims abstract description 8
239000008194 pharmaceutical composition Substances 0.000 claims abstract description 6
208000035475 disorder Diseases 0.000 claims abstract description 4
150000001412 amines Chemical class 0.000 claims description 24
210000000232 gallbladder Anatomy 0.000 claims description 15
150000003839 salts Chemical class 0.000 claims description 14
239000000546 pharmaceutical excipient Substances 0.000 claims description 10
239000012453 solvate Substances 0.000 claims description 10
150000002923 oximes Chemical class 0.000 claims description 9
JBMKRAJRQFJXSG-UHFFFAOYSA-N 3-[[5-(1-amino-3-methyl-1-oxo-2-phenylbutan-2-yl)-2,4-dioxo-1-phenyl-1,5-benzodiazepin-3-yl]carbamoylamino]benzoic acid Chemical compound C=1C=CC=CC=1C(C(C)C)(C(N)=O)N(C(C(NC(=O)NC=1C=C(C=CC=1)C(O)=O)C1=O)=O)C2=CC=CC=C2N1C1=CC=CC=C1 JBMKRAJRQFJXSG-UHFFFAOYSA-N 0.000 claims description 8
125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims description 6
239000003814 drug Substances 0.000 claims description 5
125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims description 4
239000012948 isocyanate Substances 0.000 claims description 4
150000002513 isocyanates Chemical class 0.000 claims description 4
238000004519 manufacturing process Methods 0.000 claims description 4
238000004296 chiral HPLC Methods 0.000 claims description 3
238000004517 catalytic hydrocracking Methods 0.000 claims description 2
206010012601 diabetes mellitus Diseases 0.000 claims description 2
239000003937 drug carrier Substances 0.000 claims description 2
BSCCSDNZEIHXOK-UHFFFAOYSA-N phenyl carbamate Chemical class NC(=O)OC1=CC=CC=C1 BSCCSDNZEIHXOK-UHFFFAOYSA-N 0.000 claims description 2
GEYOCULIXLDCMW-UHFFFAOYSA-N 1,2-phenylenediamine Chemical compound NC1=CC=CC=C1N GEYOCULIXLDCMW-UHFFFAOYSA-N 0.000 claims 1
JBFYUZGYRGXSFL-UHFFFAOYSA-N imidazolide Chemical compound C1=C[N-]C=N1 JBFYUZGYRGXSFL-UHFFFAOYSA-N 0.000 claims 1
238000000638 solvent extraction Methods 0.000 claims 1
238000002360 preparation method Methods 0.000 abstract description 8
239000000203 mixture Substances 0.000 description 32
YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 30
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 26
239000000243 solution Substances 0.000 description 25
HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 22
239000007787 solid Substances 0.000 description 20
CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 18
IZTQOLKUZKXIRV-YRVFCXMDSA-N sincalide Chemical compound C([C@@H](C(=O)N[C@@H](CCSC)C(=O)NCC(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(N)=O)NC(=O)[C@@H](N)CC(O)=O)C1=CC=C(OS(O)(=O)=O)C=C1 IZTQOLKUZKXIRV-YRVFCXMDSA-N 0.000 description 18
KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 17
WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 16
230000000694 effects Effects 0.000 description 16
239000004480 active ingredient Substances 0.000 description 15
XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 14
210000004027 cell Anatomy 0.000 description 14
HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 14
238000006243 chemical reaction Methods 0.000 description 13
239000002904 solvent Substances 0.000 description 13
YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 12
ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 12
101800001982 Cholecystokinin Proteins 0.000 description 11
102100025841 Cholecystokinin Human genes 0.000 description 11
229940107137 cholecystokinin Drugs 0.000 description 11
108010089448 Cholecystokinin B Receptor Proteins 0.000 description 10
IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 10
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 10
ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 10
239000000725 suspension Substances 0.000 description 10
210000001519 tissue Anatomy 0.000 description 10
102100036016 Gastrin/cholecystokinin type B receptor Human genes 0.000 description 9
239000000556 agonist Substances 0.000 description 9
239000011541 reaction mixture Substances 0.000 description 9
IMNFDUFMRHMDMM-UHFFFAOYSA-N N-Heptane Chemical compound CCCCCCC IMNFDUFMRHMDMM-UHFFFAOYSA-N 0.000 description 8
KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 8
238000003556 assay Methods 0.000 description 8
238000012360 testing method Methods 0.000 description 8
YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 8
VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 7
VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 7
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 7
239000005557 antagonist Substances 0.000 description 7
238000001914 filtration Methods 0.000 description 7
235000019359 magnesium stearate Nutrition 0.000 description 7
WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 6
102000004859 Cholecystokinin Receptors Human genes 0.000 description 6
108090001085 Cholecystokinin Receptors Proteins 0.000 description 6
OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 6
238000005481 NMR spectroscopy Methods 0.000 description 6
DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 6
JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 6
HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 6
BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 6
239000002002 slurry Substances 0.000 description 6
229920000168 Microcrystalline cellulose Polymers 0.000 description 5
WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 description 5
241000700159 Rattus Species 0.000 description 5
108010087230 Sincalide Proteins 0.000 description 5
210000004556 brain Anatomy 0.000 description 5
238000010609 cell counting kit-8 assay Methods 0.000 description 5
235000019439 ethyl acetate Nutrition 0.000 description 5
238000009472 formulation Methods 0.000 description 5
239000008108 microcrystalline cellulose Substances 0.000 description 5
229940016286 microcrystalline cellulose Drugs 0.000 description 5
235000019813 microcrystalline cellulose Nutrition 0.000 description 5
VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 5
239000003921 oil Substances 0.000 description 5
235000019198 oils Nutrition 0.000 description 5
102000005962 receptors Human genes 0.000 description 5
108020003175 receptors Proteins 0.000 description 5
GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 4
IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 4
108010089335 Cholecystokinin A Receptor Proteins 0.000 description 4
102100034927 Cholecystokinin receptor type A Human genes 0.000 description 4
RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 4
241001465754 Metazoa Species 0.000 description 4
241000699666 Mus <mouse, genus> Species 0.000 description 4
239000000872 buffer Substances 0.000 description 4
238000001514 detection method Methods 0.000 description 4
231100000673 dose–response relationship Toxicity 0.000 description 4
230000037406 food intake Effects 0.000 description 4
235000012631 food intake Nutrition 0.000 description 4
239000007924 injection Substances 0.000 description 4
238000002347 injection Methods 0.000 description 4
230000003287 optical effect Effects 0.000 description 4
CTSLXHKWHWQRSH-UHFFFAOYSA-N oxalyl chloride Chemical compound ClC(=O)C(Cl)=O CTSLXHKWHWQRSH-UHFFFAOYSA-N 0.000 description 4
210000000496 pancreas Anatomy 0.000 description 4
125000006239 protecting group Chemical group 0.000 description 4
238000000746 purification Methods 0.000 description 4
239000012488 sample solution Substances 0.000 description 4
239000011780 sodium chloride Substances 0.000 description 4
239000008109 sodium starch glycolate Substances 0.000 description 4
229940079832 sodium starch glycolate Drugs 0.000 description 4
229920003109 sodium starch glycolate Polymers 0.000 description 4
230000004580 weight loss Effects 0.000 description 4
AJHPGXZOIAYYDW-UHFFFAOYSA-N 3-(2-cyanophenyl)-2-[(2-methylpropan-2-yl)oxycarbonylamino]propanoic acid Chemical compound CC(C)(C)OC(=O)NC(C(O)=O)CC1=CC=CC=C1C#N AJHPGXZOIAYYDW-UHFFFAOYSA-N 0.000 description 3
-1 3-amino 1,5-benzodiazepine compound Chemical class 0.000 description 3
OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 3
QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 3
108010052343 Gastrins Proteins 0.000 description 3
241000282412 Homo Species 0.000 description 3
UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 3
GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 3
241000124008 Mammalia Species 0.000 description 3
235000021355 Stearic acid Nutrition 0.000 description 3
MIOPJNTWMNEORI-MHPPCMCBSA-N [(4r)-7,7-dimethyl-3-oxo-4-bicyclo[2.2.1]heptanyl]methanesulfonic acid Chemical class C1C[C@]2(CS(O)(=O)=O)C(=O)CC1C2(C)C MIOPJNTWMNEORI-MHPPCMCBSA-N 0.000 description 3
230000009286 beneficial effect Effects 0.000 description 3
230000027455 binding Effects 0.000 description 3
239000011575 calcium Substances 0.000 description 3
229910052791 calcium Inorganic materials 0.000 description 3
239000002775 capsule Substances 0.000 description 3
239000003054 catalyst Substances 0.000 description 3
239000003743 cholecystokinin B receptor antagonist Substances 0.000 description 3
238000004587 chromatography analysis Methods 0.000 description 3
230000008602 contraction Effects 0.000 description 3
229960000913 crospovidone Drugs 0.000 description 3
239000012043 crude product Substances 0.000 description 3
229940079593 drug Drugs 0.000 description 3
239000003480 eluent Substances 0.000 description 3
239000000839 emulsion Substances 0.000 description 3
238000003821 enantio-separation Methods 0.000 description 3
235000019441 ethanol Nutrition 0.000 description 3
235000019253 formic acid Nutrition 0.000 description 3
239000011521 glass Substances 0.000 description 3
229910052739 hydrogen Inorganic materials 0.000 description 3
239000001257 hydrogen Substances 0.000 description 3
229960001375 lactose Drugs 0.000 description 3
239000008101 lactose Substances 0.000 description 3
235000021056 liquid food Nutrition 0.000 description 3
238000005259 measurement Methods 0.000 description 3
QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 3
OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 3
239000012074 organic phase Substances 0.000 description 3
230000002093 peripheral effect Effects 0.000 description 3
235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 3
229920000053 polysorbate 80 Polymers 0.000 description 3
235000013809 polyvinylpolypyrrolidone Nutrition 0.000 description 3
229920000523 polyvinylpolypyrrolidone Polymers 0.000 description 3
229920000036 polyvinylpyrrolidone Polymers 0.000 description 3
235000013855 polyvinylpyrrolidone Nutrition 0.000 description 3
230000003389 potentiating effect Effects 0.000 description 3
UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 3
230000036186 satiety Effects 0.000 description 3
235000019627 satiety Nutrition 0.000 description 3
239000000600 sorbitol Substances 0.000 description 3
235000010356 sorbitol Nutrition 0.000 description 3
239000008117 stearic acid Substances 0.000 description 3
230000001988 toxicity Effects 0.000 description 3
231100000419 toxicity Toxicity 0.000 description 3
RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 2
QAMXRSYGKZAIDC-UHFFFAOYSA-N 3-isocyanobenzoic acid Chemical compound OC(=O)C1=CC=CC([N+]#[C-])=C1 QAMXRSYGKZAIDC-UHFFFAOYSA-N 0.000 description 2
208000019901 Anxiety disease Diseases 0.000 description 2
108091003079 Bovine Serum Albumin Proteins 0.000 description 2
244000025254 Cannabis sativa Species 0.000 description 2
241000700199 Cavia porcellus Species 0.000 description 2
241000557626 Corvus corax Species 0.000 description 2
FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 2
LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 2
102400000921 Gastrin Human genes 0.000 description 2
108010010803 Gelatin Proteins 0.000 description 2
WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
101000946804 Homo sapiens Cholecystokinin receptor type A Proteins 0.000 description 2
206010020880 Hypertrophy Diseases 0.000 description 2
235000010643 Leucaena leucocephala Nutrition 0.000 description 2
240000007472 Leucaena leucocephala Species 0.000 description 2
BZLVMXJERCGZMT-UHFFFAOYSA-N Methyl tert-butyl ether Chemical compound COC(C)(C)C BZLVMXJERCGZMT-UHFFFAOYSA-N 0.000 description 2
241000699670 Mus sp. Species 0.000 description 2
241000283984 Rodentia Species 0.000 description 2
DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 2
230000001594 aberrant effect Effects 0.000 description 2
230000002159 abnormal effect Effects 0.000 description 2
OIPILFWXSMYKGL-UHFFFAOYSA-N acetylcholine Chemical compound CC(=O)OCC[N+](C)(C)C OIPILFWXSMYKGL-UHFFFAOYSA-N 0.000 description 2
229960004373 acetylcholine Drugs 0.000 description 2
230000004913 activation Effects 0.000 description 2
VZTDIZULWFCMLS-UHFFFAOYSA-N ammonium formate Chemical compound [NH4+].[O-]C=O VZTDIZULWFCMLS-UHFFFAOYSA-N 0.000 description 2
238000004458 analytical method Methods 0.000 description 2
230000036506 anxiety Effects 0.000 description 2
235000021407 appetite control Nutrition 0.000 description 2
239000012298 atmosphere Substances 0.000 description 2
229910002091 carbon monoxide Inorganic materials 0.000 description 2
PFKFTWBEEFSNDU-UHFFFAOYSA-N carbonyldiimidazole Chemical compound C1=CN=CN1C(=O)N1C=CN=C1 PFKFTWBEEFSNDU-UHFFFAOYSA-N 0.000 description 2
210000003169 central nervous system Anatomy 0.000 description 2
AOXOCDRNSPFDPE-UKEONUMOSA-N chembl413654 Chemical compound C([C@H](C(=O)NCC(=O)N[C@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@H](CCSC)C(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CC=1C=CC=CC=1)C(N)=O)NC(=O)[C@@H](C)NC(=O)[C@@H](CCC(O)=O)NC(=O)[C@@H](CCC(O)=O)NC(=O)[C@@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H]1N(CCC1)C(=O)CNC(=O)[C@@H](N)CCC(O)=O)C1=CC=C(O)C=C1 AOXOCDRNSPFDPE-UKEONUMOSA-N 0.000 description 2
239000003153 chemical reaction reagent Substances 0.000 description 2
229940075614 colloidal silicon dioxide Drugs 0.000 description 2
239000002299 complementary DNA Substances 0.000 description 2
238000007796 conventional method Methods 0.000 description 2
230000009089 cytolysis Effects 0.000 description 2
HPNMFZURTQLUMO-UHFFFAOYSA-N diethylamine Chemical compound CCNCC HPNMFZURTQLUMO-UHFFFAOYSA-N 0.000 description 2
238000004821 distillation Methods 0.000 description 2
238000001035 drying Methods 0.000 description 2
150000002148 esters Chemical class 0.000 description 2
DEFVIWRASFVYLL-UHFFFAOYSA-N ethylene glycol bis(2-aminoethyl)tetraacetic acid Chemical compound OC(=O)CN(CC(O)=O)CCOCCOCCN(CC(O)=O)CC(O)=O DEFVIWRASFVYLL-UHFFFAOYSA-N 0.000 description 2
230000029142 excretion Effects 0.000 description 2
238000011049 filling Methods 0.000 description 2
239000000706 filtrate Substances 0.000 description 2
235000013305 food Nutrition 0.000 description 2
230000027119 gastric acid secretion Effects 0.000 description 2
239000008273 gelatin Substances 0.000 description 2
229920000159 gelatin Polymers 0.000 description 2
229940014259 gelatin Drugs 0.000 description 2
235000019322 gelatine Nutrition 0.000 description 2
235000011852 gelatine desserts Nutrition 0.000 description 2
BRZYSWJRSDMWLG-CAXSIQPQSA-N geneticin Chemical compound O1C[C@@](O)(C)[C@H](NC)[C@@H](O)[C@H]1O[C@@H]1[C@@H](O)[C@H](O[C@@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](C(C)O)O2)N)[C@@H](N)C[C@H]1N BRZYSWJRSDMWLG-CAXSIQPQSA-N 0.000 description 2
229940088597 hormone Drugs 0.000 description 2
239000005556 hormone Substances 0.000 description 2
230000007062 hydrolysis Effects 0.000 description 2
238000006460 hydrolysis reaction Methods 0.000 description 2
150000007928 imidazolide derivatives Chemical class 0.000 description 2
238000000338 in vitro Methods 0.000 description 2
238000001727 in vivo Methods 0.000 description 2
239000004615 ingredient Substances 0.000 description 2
230000003834 intracellular effect Effects 0.000 description 2
239000012669 liquid formulation Substances 0.000 description 2
230000014759 maintenance of location Effects 0.000 description 2
229910052757 nitrogen Inorganic materials 0.000 description 2
229940100688 oral solution Drugs 0.000 description 2
229940100692 oral suspension Drugs 0.000 description 2
229910052763 palladium Inorganic materials 0.000 description 2
239000002245 particle Substances 0.000 description 2
239000008188 pellet Substances 0.000 description 2
230000035479 physiological effects, processes and functions Effects 0.000 description 2
229940068918 polyethylene glycol 400 Drugs 0.000 description 2
229940069328 povidone Drugs 0.000 description 2
239000000843 powder Substances 0.000 description 2
230000036316 preload Effects 0.000 description 2
108090000765 processed proteins & peptides Proteins 0.000 description 2
239000000047 product Substances 0.000 description 2
102000004169 proteins and genes Human genes 0.000 description 2
108090000623 proteins and genes Proteins 0.000 description 2
239000000523 sample Substances 0.000 description 2
230000028327 secretion Effects 0.000 description 2
238000003756 stirring Methods 0.000 description 2
235000020357 syrup Nutrition 0.000 description 2
239000006188 syrup Substances 0.000 description 2
125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 2
210000001186 vagus nerve Anatomy 0.000 description 2
238000005406 washing Methods 0.000 description 2
ZORQXIQZAOLNGE-UHFFFAOYSA-N 1,1-difluorocyclohexane Chemical compound FC1(F)CCCCC1 ZORQXIQZAOLNGE-UHFFFAOYSA-N 0.000 description 1
IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
238000005160 1H NMR spectroscopy Methods 0.000 description 1
XUCSQYPDVPHCIF-UHFFFAOYSA-N 2-(2-anilinoanilino)-n-phenyl-n-propan-2-ylacetamide Chemical compound C=1C=CC=CC=1N(C(C)C)C(=O)CNC1=CC=CC=C1NC1=CC=CC=C1 XUCSQYPDVPHCIF-UHFFFAOYSA-N 0.000 description 1
MZCFNFOLSNPXNC-UHFFFAOYSA-N 2-(3-amino-2,4-dioxo-5-phenyl-1,5-benzodiazepin-1-yl)-n-phenyl-n-propan-2-ylacetamide;(7,7-dimethyl-3-oxo-4-bicyclo[2.2.1]heptanyl)methanesulfonic acid Chemical compound C1CC2(CS(O)(=O)=O)C(=O)CC1C2(C)C.C=1C=CC=CC=1N(C(C)C)C(=O)CN(C(C(N)C1=O)=O)C2=CC=CC=C2N1C1=CC=CC=C1 MZCFNFOLSNPXNC-UHFFFAOYSA-N 0.000 description 1
JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 1
QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 1
CSDSSGBPEUDDEE-UHFFFAOYSA-N 2-formylpyridine Chemical compound O=CC1=CC=CC=N1 CSDSSGBPEUDDEE-UHFFFAOYSA-N 0.000 description 1
DRWXKOOIIZJHEG-UHFFFAOYSA-N 2-phenylmethoxyiminopropanedioic acid Chemical compound OC(=O)C(C(O)=O)=NOCC1=CC=CC=C1 DRWXKOOIIZJHEG-UHFFFAOYSA-N 0.000 description 1
AFPHTEQTJZKQAQ-UHFFFAOYSA-N 3-nitrobenzoic acid Chemical compound OC(=O)C1=CC=CC([N+]([O-])=O)=C1 AFPHTEQTJZKQAQ-UHFFFAOYSA-N 0.000 description 1
NXTNASSYJUXJDV-UHFFFAOYSA-N 3-nitrobenzoyl chloride Chemical compound [O-][N+](=O)C1=CC=CC(C(Cl)=O)=C1 NXTNASSYJUXJDV-UHFFFAOYSA-N 0.000 description 1
235000019489 Almond oil Nutrition 0.000 description 1
WSVLPVUVIUVCRA-KPKNDVKVSA-N Alpha-lactose monohydrate Chemical compound O.O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O WSVLPVUVIUVCRA-KPKNDVKVSA-N 0.000 description 1
241000416162 Astragalus gummifer Species 0.000 description 1
229940122737 CCK B receptor agonist Drugs 0.000 description 1
229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
229920002261 Corn starch Polymers 0.000 description 1
FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
102000004190 Enzymes Human genes 0.000 description 1
108090000790 Enzymes Proteins 0.000 description 1
102000052874 Gastrin receptors Human genes 0.000 description 1
244000068988 Glycine max Species 0.000 description 1
235000010469 Glycine max Nutrition 0.000 description 1
239000007995 HEPES buffer Substances 0.000 description 1
101001021397 Homo sapiens Gastrin/cholecystokinin type B receptor Proteins 0.000 description 1
239000004354 Hydroxyethyl cellulose Substances 0.000 description 1
229920000663 Hydroxyethyl cellulose Polymers 0.000 description 1
AVXURJPOCDRRFD-UHFFFAOYSA-N Hydroxylamine Chemical compound ON AVXURJPOCDRRFD-UHFFFAOYSA-N 0.000 description 1
206010020772 Hypertension Diseases 0.000 description 1
206010021518 Impaired gastric emptying Diseases 0.000 description 1
244000199265 Inga micheliana Species 0.000 description 1
235000012603 Inga micheliana Nutrition 0.000 description 1
239000005909 Kieselgur Substances 0.000 description 1
CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 1
OFOBLEOULBTSOW-UHFFFAOYSA-L Malonate Chemical compound [O-]C(=O)CC([O-])=O OFOBLEOULBTSOW-UHFFFAOYSA-L 0.000 description 1
IEKOTSCYBBDIJC-UHFFFAOYSA-N N(2)-(3,4-dichlorobenzoyl)-N,N-dipentyl-alpha-glutamine Chemical compound CCCCCN(CCCCC)C(=O)C(CCC(O)=O)NC(=O)C1=CC=C(Cl)C(Cl)=C1 IEKOTSCYBBDIJC-UHFFFAOYSA-N 0.000 description 1
102000057297 Pepsin A Human genes 0.000 description 1
108090000284 Pepsin A Proteins 0.000 description 1
YGYAWVDWMABLBF-UHFFFAOYSA-N Phosgene Chemical compound ClC(Cl)=O YGYAWVDWMABLBF-UHFFFAOYSA-N 0.000 description 1
239000002202 Polyethylene glycol Substances 0.000 description 1
DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
229920002472 Starch Polymers 0.000 description 1
239000004809 Teflon Substances 0.000 description 1
229920006362 Teflon® Polymers 0.000 description 1
229920001615 Tragacanth Polymers 0.000 description 1
101710162629 Trypsin inhibitor Proteins 0.000 description 1
229940122618 Trypsin inhibitor Drugs 0.000 description 1
HMNZFMSWFCAGGW-XPWSMXQVSA-N [3-[hydroxy(2-hydroxyethoxy)phosphoryl]oxy-2-[(e)-octadec-9-enoyl]oxypropyl] (e)-octadec-9-enoate Chemical compound CCCCCCCC\C=C\CCCCCCCC(=O)OCC(COP(O)(=O)OCCO)OC(=O)CCCCCCC\C=C\CCCCCCCC HMNZFMSWFCAGGW-XPWSMXQVSA-N 0.000 description 1
238000010521 absorption reaction Methods 0.000 description 1
239000002253 acid Substances 0.000 description 1
239000000654 additive Substances 0.000 description 1
239000000853 adhesive Substances 0.000 description 1
230000001070 adhesive effect Effects 0.000 description 1
239000008168 almond oil Substances 0.000 description 1
CEGOLXSVJUTHNZ-UHFFFAOYSA-K aluminium tristearate Chemical compound [Al+3].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CEGOLXSVJUTHNZ-UHFFFAOYSA-K 0.000 description 1
229940063655 aluminum stearate Drugs 0.000 description 1
229960004977 anhydrous lactose Drugs 0.000 description 1
208000022531 anorexia Diseases 0.000 description 1
230000000767 anti-ulcer Effects 0.000 description 1
239000002249 anxiolytic agent Substances 0.000 description 1
235000019789 appetite Nutrition 0.000 description 1
230000036528 appetite Effects 0.000 description 1
230000004596 appetite loss Effects 0.000 description 1
239000000010 aprotic solvent Substances 0.000 description 1
239000008346 aqueous phase Substances 0.000 description 1
238000003287 bathing Methods 0.000 description 1
IDIPWEYIBKUDNY-UHFFFAOYSA-N benzenesulfonyl fluoride Chemical compound FS(=O)(=O)C1=CC=CC=C1 IDIPWEYIBKUDNY-UHFFFAOYSA-N 0.000 description 1
125000003310 benzodiazepinyl group Chemical group N1N=C(C=CC2=C1C=CC=C2)* 0.000 description 1
125000000051 benzyloxy group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])O* 0.000 description 1
239000011230 binding agent Substances 0.000 description 1
239000012148 binding buffer Substances 0.000 description 1
238000004166 bioassay Methods 0.000 description 1
230000004071 biological effect Effects 0.000 description 1
229940098773 bovine serum albumin Drugs 0.000 description 1
210000004899 c-terminal region Anatomy 0.000 description 1
239000001506 calcium phosphate Substances 0.000 description 1
229910000389 calcium phosphate Inorganic materials 0.000 description 1
235000011010 calcium phosphates Nutrition 0.000 description 1
239000001768 carboxy methyl cellulose Substances 0.000 description 1
235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
239000008112 carboxymethyl-cellulose Substances 0.000 description 1
239000000969 carrier Substances 0.000 description 1
210000000170 cell membrane Anatomy 0.000 description 1
238000005119 centrifugation Methods 0.000 description 1
238000012512 characterization method Methods 0.000 description 1
239000007795 chemical reaction product Substances 0.000 description 1
239000003795 chemical substances by application Substances 0.000 description 1
238000004140 cleaning Methods 0.000 description 1
238000003776 cleavage reaction Methods 0.000 description 1
210000001728 clone cell Anatomy 0.000 description 1
229940110456 cocoa butter Drugs 0.000 description 1
235000019868 cocoa butter Nutrition 0.000 description 1
239000003240 coconut oil Substances 0.000 description 1
235000019864 coconut oil Nutrition 0.000 description 1
239000012230 colorless oil Substances 0.000 description 1
210000002808 connective tissue Anatomy 0.000 description 1
239000008120 corn starch Substances 0.000 description 1
238000002425 crystallisation Methods 0.000 description 1
230000008025 crystallization Effects 0.000 description 1
238000000354 decomposition reaction Methods 0.000 description 1
206010061428 decreased appetite Diseases 0.000 description 1
239000003405 delayed action preparation Substances 0.000 description 1
239000011928 denatured alcohol Substances 0.000 description 1
238000011161 development Methods 0.000 description 1
239000008121 dextrose Substances 0.000 description 1
DBKKFIIYQGGHJO-UHFFFAOYSA-N diethyl 2-oxopropanedioate Chemical compound CCOC(=O)C(=O)C(=O)OCC DBKKFIIYQGGHJO-UHFFFAOYSA-N 0.000 description 1
MAIHHKIFKDJYHV-UHFFFAOYSA-N diethyl 2-phenylmethoxyiminopropanedioate Chemical compound CCOC(=O)C(C(=O)OCC)=NOCC1=CC=CC=C1 MAIHHKIFKDJYHV-UHFFFAOYSA-N 0.000 description 1
125000004177 diethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
238000010790 dilution Methods 0.000 description 1
239000012895 dilution Substances 0.000 description 1
ZZVUWRFHKOJYTH-UHFFFAOYSA-N diphenhydramine Chemical group C=1C=CC=CC=1C(OCCN(C)C)C1=CC=CC=C1 ZZVUWRFHKOJYTH-UHFFFAOYSA-N 0.000 description 1
239000007884 disintegrant Substances 0.000 description 1
239000002270 dispersing agent Substances 0.000 description 1
238000006073 displacement reaction Methods 0.000 description 1
238000009826 distribution Methods 0.000 description 1
239000008157 edible vegetable oil Substances 0.000 description 1
239000003995 emulsifying agent Substances 0.000 description 1
239000002702 enteric coating Substances 0.000 description 1
238000009505 enteric coating Methods 0.000 description 1
229940088598 enzyme Drugs 0.000 description 1
BEFDCLMNVWHSGT-UHFFFAOYSA-N ethenylcyclopentane Chemical compound C=CC1CCCC1 BEFDCLMNVWHSGT-UHFFFAOYSA-N 0.000 description 1
230000005284 excitation Effects 0.000 description 1
230000001747 exhibiting effect Effects 0.000 description 1
238000002474 experimental method Methods 0.000 description 1
239000003925 fat Substances 0.000 description 1
235000019197 fats Nutrition 0.000 description 1
230000004720 fertilization Effects 0.000 description 1
239000012091 fetal bovine serum Substances 0.000 description 1
239000000835 fiber Substances 0.000 description 1
239000000945 filler Substances 0.000 description 1
238000013100 final test Methods 0.000 description 1
238000005194 fractionation Methods 0.000 description 1
210000004211 gastric acid Anatomy 0.000 description 1
230000030136 gastric emptying Effects 0.000 description 1
OKGNKPYIPKMGLR-ZPCKCTIPSA-N gastrins Chemical class C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@H](C(=O)N[C@@H](C)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(N)=O)C(=O)NCC(=O)N1CCC[C@H]1C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)NCC(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(N)=O)C(C)C)NC(=O)[C@H]1N(CCC1)C(=O)[C@H]1N(CCC1)C(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](CC(C)C)NC(=O)[C@H]1N(CCC1)C(=O)[C@H]1NC(=O)CC1)C1=CN=CN1 OKGNKPYIPKMGLR-ZPCKCTIPSA-N 0.000 description 1
239000003629 gastrointestinal hormone Substances 0.000 description 1
210000001035 gastrointestinal tract Anatomy 0.000 description 1
239000000499 gel Substances 0.000 description 1
239000007903 gelatin capsule Substances 0.000 description 1
230000014509 gene expression Effects 0.000 description 1
239000008103 glucose Substances 0.000 description 1
235000001727 glucose Nutrition 0.000 description 1
125000005456 glyceride group Chemical group 0.000 description 1
PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical group [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 1
239000008187 granular material Substances 0.000 description 1
150000004820 halides Chemical class 0.000 description 1
150000005826 halohydrocarbons Chemical class 0.000 description 1
238000011597 hartley guinea pig Methods 0.000 description 1
238000010438 heat treatment Methods 0.000 description 1
239000003906 humectant Substances 0.000 description 1
235000003642 hunger Nutrition 0.000 description 1
230000002209 hydrophobic effect Effects 0.000 description 1
WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 description 1
235000019447 hydroxyethyl cellulose Nutrition 0.000 description 1
210000003405 ileum Anatomy 0.000 description 1
125000001841 imino group Chemical group [H]N=* 0.000 description 1
238000002513 implantation Methods 0.000 description 1
238000000099 in vitro assay Methods 0.000 description 1
238000011065 in-situ storage Methods 0.000 description 1
238000011534 incubation Methods 0.000 description 1
238000001802 infusion Methods 0.000 description 1
239000003112 inhibitor Substances 0.000 description 1
230000000968 intestinal effect Effects 0.000 description 1
238000010255 intramuscular injection Methods 0.000 description 1
239000007927 intramuscular injection Substances 0.000 description 1
239000003456 ion exchange resin Substances 0.000 description 1
229920003303 ion-exchange polymer Polymers 0.000 description 1
230000007794 irritation Effects 0.000 description 1
229960001021 lactose monohydrate Drugs 0.000 description 1
235000010445 lecithin Nutrition 0.000 description 1
239000000787 lecithin Substances 0.000 description 1
229940067606 lecithin Drugs 0.000 description 1
239000003446 ligand Substances 0.000 description 1
239000007788 liquid Substances 0.000 description 1
230000003910 liver physiology Effects 0.000 description 1
230000007774 longterm Effects 0.000 description 1
229950000165 lorglumide Drugs 0.000 description 1
208000019017 loss of appetite Diseases 0.000 description 1
235000021266 loss of appetite Nutrition 0.000 description 1
239000000314 lubricant Substances 0.000 description 1
238000013289 male long evans rat Methods 0.000 description 1
239000000463 material Substances 0.000 description 1
OFXSXYCSPVKZPF-UHFFFAOYSA-N methoxyperoxymethane Chemical compound COOOC OFXSXYCSPVKZPF-UHFFFAOYSA-N 0.000 description 1
DZNKOAWEHDKBEP-UHFFFAOYSA-N methyl 2-[6-[bis(2-methoxy-2-oxoethyl)amino]-5-[2-[2-[bis(2-methoxy-2-oxoethyl)amino]-5-methylphenoxy]ethoxy]-1-benzofuran-2-yl]-1,3-oxazole-5-carboxylate Chemical compound COC(=O)CN(CC(=O)OC)C1=CC=C(C)C=C1OCCOC(C(=C1)N(CC(=O)OC)CC(=O)OC)=CC2=C1OC(C=1OC(=CN=1)C(=O)OC)=C2 DZNKOAWEHDKBEP-UHFFFAOYSA-N 0.000 description 1
229920000609 methyl cellulose Polymers 0.000 description 1
125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
239000004292 methyl p-hydroxybenzoate Substances 0.000 description 1
235000010270 methyl p-hydroxybenzoate Nutrition 0.000 description 1
230000011987 methylation Effects 0.000 description 1
238000007069 methylation reaction Methods 0.000 description 1
239000001923 methylcellulose Substances 0.000 description 1
235000010981 methylcellulose Nutrition 0.000 description 1
SYSQUGFVNFXIIT-UHFFFAOYSA-N n-[4-(1,3-benzoxazol-2-yl)phenyl]-4-nitrobenzenesulfonamide Chemical class C1=CC([N+](=O)[O-])=CC=C1S(=O)(=O)NC1=CC=C(C=2OC3=CC=CC=C3N=2)C=C1 SYSQUGFVNFXIIT-UHFFFAOYSA-N 0.000 description 1
210000004126 nerve fiber Anatomy 0.000 description 1
239000002858 neurotransmitter agent Substances 0.000 description 1
150000002825 nitriles Chemical class 0.000 description 1
230000009871 nonspecific binding Effects 0.000 description 1
231100000252 nontoxic Toxicity 0.000 description 1
230000003000 nontoxic effect Effects 0.000 description 1
XYEOALKITRFCJJ-UHFFFAOYSA-N o-benzylhydroxylamine Chemical compound NOCC1=CC=CC=C1 XYEOALKITRFCJJ-UHFFFAOYSA-N 0.000 description 1
150000004987 o-phenylenediamines Chemical class 0.000 description 1
229940126701 oral medication Drugs 0.000 description 1
239000012044 organic layer Substances 0.000 description 1
XEEVLJKYYUVTRC-UHFFFAOYSA-N oxomalonic acid Chemical compound OC(=O)C(=O)C(O)=O XEEVLJKYYUVTRC-UHFFFAOYSA-N 0.000 description 1
238000007911 parenteral administration Methods 0.000 description 1
230000007170 pathology Effects 0.000 description 1
229940111202 pepsin Drugs 0.000 description 1
210000001428 peripheral nervous system Anatomy 0.000 description 1
230000035699 permeability Effects 0.000 description 1
230000000144 pharmacologic effect Effects 0.000 description 1
239000012071 phase Substances 0.000 description 1
238000005191 phase separation Methods 0.000 description 1
AHWALFGBDFAJAI-UHFFFAOYSA-N phenyl carbonochloridate Chemical class ClC(=O)OC1=CC=CC=C1 AHWALFGBDFAJAI-UHFFFAOYSA-N 0.000 description 1
125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 1
QIIPQYDSKRYMFG-UHFFFAOYSA-N phenyl hydrogen carbonate Chemical class OC(=O)OC1=CC=CC=C1 QIIPQYDSKRYMFG-UHFFFAOYSA-N 0.000 description 1
239000002504 physiological saline solution Substances 0.000 description 1
229920001223 polyethylene glycol Polymers 0.000 description 1
229920000642 polymer Polymers 0.000 description 1
239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 description 1
229940068968 polysorbate 80 Drugs 0.000 description 1
239000001267 polyvinylpyrrolidone Substances 0.000 description 1
LPNYRYFBWFDTMA-UHFFFAOYSA-N potassium tert-butoxide Chemical compound [K+].CC(C)(C)[O-] LPNYRYFBWFDTMA-UHFFFAOYSA-N 0.000 description 1
229920001592 potato starch Polymers 0.000 description 1
239000003755 preservative agent Substances 0.000 description 1
230000002265 prevention Effects 0.000 description 1
DBABZHXKTCFAPX-UHFFFAOYSA-N probenecid Chemical compound CCCN(CCC)S(=O)(=O)C1=CC=C(C(O)=O)C=C1 DBABZHXKTCFAPX-UHFFFAOYSA-N 0.000 description 1
229960003081 probenecid Drugs 0.000 description 1
102000004196 processed proteins & peptides Human genes 0.000 description 1
230000000750 progressive effect Effects 0.000 description 1
230000002035 prolonged effect Effects 0.000 description 1
230000000069 prophylactic effect Effects 0.000 description 1
239000004405 propyl p-hydroxybenzoate Substances 0.000 description 1
235000010232 propyl p-hydroxybenzoate Nutrition 0.000 description 1
QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 1
238000000159 protein binding assay Methods 0.000 description 1
210000001187 pylorus Anatomy 0.000 description 1
230000001698 pyrogenic effect Effects 0.000 description 1
238000010791 quenching Methods 0.000 description 1
238000001525 receptor binding assay Methods 0.000 description 1
238000011084 recovery Methods 0.000 description 1
230000007017 scission Effects 0.000 description 1
239000000741 silica gel Substances 0.000 description 1
229910002027 silica gel Inorganic materials 0.000 description 1
239000000377 silicon dioxide Substances 0.000 description 1
235000020374 simple syrup Nutrition 0.000 description 1
238000004088 simulation Methods 0.000 description 1
239000011734 sodium Substances 0.000 description 1
235000019333 sodium laurylsulphate Nutrition 0.000 description 1
229940080313 sodium starch Drugs 0.000 description 1
238000000527 sonication Methods 0.000 description 1
239000004334 sorbic acid Substances 0.000 description 1
235000010199 sorbic acid Nutrition 0.000 description 1
229940075582 sorbic acid Drugs 0.000 description 1
239000001593 sorbitan monooleate Substances 0.000 description 1
235000011069 sorbitan monooleate Nutrition 0.000 description 1
229940035049 sorbitan monooleate Drugs 0.000 description 1
229960002920 sorbitol Drugs 0.000 description 1
235000015096 spirit Nutrition 0.000 description 1
239000003381 stabilizer Substances 0.000 description 1
229910001220 stainless steel Inorganic materials 0.000 description 1
239000010935 stainless steel Substances 0.000 description 1
239000008107 starch Substances 0.000 description 1
229940032147 starch Drugs 0.000 description 1
235000019698 starch Nutrition 0.000 description 1
230000001954 sterilising effect Effects 0.000 description 1
230000000638 stimulation Effects 0.000 description 1
210000002784 stomach Anatomy 0.000 description 1
235000000346 sugar Nutrition 0.000 description 1
150000008163 sugars Chemical class 0.000 description 1
239000006228 supernatant Substances 0.000 description 1
239000000829 suppository Substances 0.000 description 1
239000002511 suppository base Substances 0.000 description 1
239000000375 suspending agent Substances 0.000 description 1
238000003786 synthesis reaction Methods 0.000 description 1
239000000454 talc Substances 0.000 description 1
235000012222 talc Nutrition 0.000 description 1
229910052623 talc Inorganic materials 0.000 description 1
150000003512 tertiary amines Chemical class 0.000 description 1
230000001225 therapeutic effect Effects 0.000 description 1
238000002560 therapeutic procedure Methods 0.000 description 1
231100000331 toxic Toxicity 0.000 description 1
230000002588 toxic effect Effects 0.000 description 1
235000010487 tragacanth Nutrition 0.000 description 1
239000000196 tragacanth Substances 0.000 description 1
229940116362 tragacanth Drugs 0.000 description 1
238000001890 transfection Methods 0.000 description 1
238000002054 transplantation Methods 0.000 description 1
QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
UCPYLLCMEDAXFR-UHFFFAOYSA-N triphosgene Chemical compound ClC(Cl)(Cl)OC(=O)OC(Cl)(Cl)Cl UCPYLLCMEDAXFR-UHFFFAOYSA-N 0.000 description 1
239000002753 trypsin inhibitor Substances 0.000 description 1
238000000825 ultraviolet detection Methods 0.000 description 1
210000003954 umbilical cord Anatomy 0.000 description 1
230000003442 weekly effect Effects 0.000 description 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D243/00—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms
- C07D243/06—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4
- C07D243/10—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4 condensed with carbocyclic rings or ring systems
- C07D243/12—1,5-Benzodiazepines; Hydrogenated 1,5-benzodiazepines
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Medicinal Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
General Health & Medical Sciences (AREA)
Engineering & Computer Science (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
Bioinformatics & Cheminformatics (AREA)
Diabetes (AREA)
Obesity (AREA)
Hematology (AREA)
Endocrinology (AREA)
Emergency Medicine (AREA)
Child & Adolescent Psychology (AREA)
Gastroenterology & Hepatology (AREA)
Epidemiology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Plural Heterocyclic Compounds (AREA)
Nitrogen Condensed Heterocyclic Rings (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

KR1020017014075A 1999-05-06 2000-05-04 1,5-벤조디아제핀 유도체 Withdrawn KR20020012567A (ko)

Applications Claiming Priority (5)

Application Number	Priority Date	Filing Date	Title
GB9910366.5		1999-05-06
GBGB9910366.5A GB9910366D0 (en)	1999-05-06	1999-05-06	1,5-Benzodiazepine Derivatives
GBGB0008179.4A GB0008179D0 (en)	2000-04-05	2000-04-05	Chemical process
GB0008179.4		2000-04-05
PCT/EP2000/003982 WO2000068209A2 (fr)	1999-05-06	2000-05-04	Derives de 1,5-benzodiazepines

Publications (1)

Publication Number	Publication Date
KR20020012567A true KR20020012567A (ko)	2002-02-16

Family

ID=26244033

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
KR1020017014075A Withdrawn KR20020012567A (ko)	1999-05-06	2000-05-04	1,5-벤조디아제핀 유도체

Country Status (21)

Country	Link
EP (1)	EP1212305A2 (fr)
JP (1)	JP2002544200A (fr)
KR (1)	KR20020012567A (fr)
CN (1)	CN1161345C (fr)
AR (1)	AR022044A1 (fr)
AU (1)	AU4754800A (fr)
BR (1)	BR0010338A (fr)
CA (1)	CA2370801A1 (fr)
CO (1)	CO5170461A1 (fr)
CZ (1)	CZ20013988A3 (fr)
HK (1)	HK1046138A1 (fr)
HU (1)	HUP0201181A3 (fr)
IL (1)	IL146124A0 (fr)
MX (1)	MXPA01011267A (fr)
MY (1)	MY138319A (fr)
NO (1)	NO20015397D0 (fr)
NZ (1)	NZ515048A (fr)
PE (1)	PE20010110A1 (fr)
PL (1)	PL351546A1 (fr)
TR (1)	TR200103169T2 (fr)
WO (1)	WO2000068209A2 (fr)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO2005035793A2 (fr) *	2003-10-09	2005-04-21	Decode Genetics Ehf.	Marqueurs et haplotypes de cckar associes a des etats d'excedent de poids
CA2568056A1 (fr)	2004-05-25	2005-12-08	Pfizer Products Inc.	Derives de tetraazabenzo[e]azulene et analogues de ceux-ci
JP2022552655A (ja)	2019-10-07	2022-12-19	キャリーオペ，インク．	Ｇｐｒ１１９アゴニスト
PH12022552277A1 (en)	2020-02-28	2024-03-04	Kallyope Inc	Gpr40 agonists

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
GB9307833D0 (en) *	1993-04-15	1993-06-02	Glaxo Inc	Modulators of cholecystokinin and gastrin

2000
- 2000-05-03 AR ARP000102119A patent/AR022044A1/es unknown
- 2000-05-04 JP JP2000617189A patent/JP2002544200A/ja active Pending
- 2000-05-04 CA CA002370801A patent/CA2370801A1/fr not_active Abandoned
- 2000-05-04 MY MYPI20001917A patent/MY138319A/en unknown
- 2000-05-04 HK HK02107684.4A patent/HK1046138A1/zh unknown
- 2000-05-04 TR TR2001/03169T patent/TR200103169T2/xx unknown
- 2000-05-04 WO PCT/EP2000/003982 patent/WO2000068209A2/fr not_active Ceased
- 2000-05-04 KR KR1020017014075A patent/KR20020012567A/ko not_active Withdrawn
- 2000-05-04 BR BR0010338-1A patent/BR0010338A/pt not_active IP Right Cessation
- 2000-05-04 PL PL00351546A patent/PL351546A1/xx not_active Application Discontinuation
- 2000-05-04 CO CO00031982A patent/CO5170461A1/es not_active Application Discontinuation
- 2000-05-04 PE PE2000000415A patent/PE20010110A1/es not_active Application Discontinuation
- 2000-05-04 EP EP00929488A patent/EP1212305A2/fr not_active Withdrawn
- 2000-05-04 CZ CZ20013988A patent/CZ20013988A3/cs unknown
- 2000-05-04 NZ NZ515048A patent/NZ515048A/xx unknown
- 2000-05-04 MX MXPA01011267A patent/MXPA01011267A/es not_active Application Discontinuation
- 2000-05-04 IL IL14612400A patent/IL146124A0/xx unknown
- 2000-05-04 HU HU0201181A patent/HUP0201181A3/hu unknown
- 2000-05-04 CN CNB008099324A patent/CN1161345C/zh not_active Expired - Fee Related
- 2000-05-04 AU AU47548/00A patent/AU4754800A/en not_active Abandoned
2001
- 2001-11-05 NO NO20015397A patent/NO20015397D0/no not_active Application Discontinuation

Also Published As

Publication number	Publication date
CA2370801A1 (fr)	2000-11-16
AU4754800A (en)	2000-11-21
PL351546A1 (en)	2003-05-05
MY138319A (en)	2009-05-29
JP2002544200A (ja)	2002-12-24
WO2000068209A2 (fr)	2000-11-16
BR0010338A (pt)	2002-02-13
HUP0201181A3 (en)	2003-10-28
MXPA01011267A (es)	2002-05-06
IL146124A0 (en)	2002-07-25
NO20015397L (no)	2001-11-05
AR022044A1 (es)	2002-09-04
HUP0201181A2 (hu)	2002-12-28
TR200103169T2 (tr)	2002-04-22
EP1212305A2 (fr)	2002-06-12
CN1362949A (zh)	2002-08-07
CN1161345C (zh)	2004-08-11
CZ20013988A3 (cs)	2002-02-13
CO5170461A1 (es)	2002-06-27
WO2000068209A3 (fr)	2001-03-01
NZ515048A (en)	2004-01-30
NO20015397D0 (no)	2001-11-05
PE20010110A1 (es)	2001-03-05
HK1046138A1 (zh)	2002-12-27

Publication	Publication Date	Title
JP2603214B2 (ja)	1997-04-23	ベンゾジアゼピン類似体
US4880938A (en)	1989-11-14	Amino acid analogs
DE69426624T2 (de)	2001-06-21	1,5 benzodiazepinoderivate mit cck-antagonisierender und oder agonisierender wirkung
EP0652871B1 (fr)	2001-10-17	Derives de benzodiazepine
US5220017A (en)	1993-06-15	Cholecystokinin antagonists
US5451582A (en)	1995-09-19	Benzodiazepine derivatives, compositions containing them and their use in therapy
US7271162B2 (en)	2007-09-18	Cycloocta[b][1,4]diazepino[6,7,1-hi]indoles and derivatives
EP0984960B1 (fr)	2003-02-05	N-triazolyl-2-indolecarboxamides et leur utilisation comme agonistes de cck-a
US6858604B2 (en)	2005-02-22	Cyclohepta[b][1,4]diazepino[6,7,1-hi]indoles and derivatives
EP0169392A2 (fr)	1986-01-29	Triazolobenzodiazépines et compositions pharmaceutiques les contenant
JPH08505120A (ja)	1996-06-04	ベンゾジアゼピン誘導体
KR100347287B1 (ko)	2002-12-06	콜레시스토키닌또는가스트린의길항물질로서유용한1,5-벤조디아제핀유도체
US5218114A (en)	1993-06-08	Cholecystokinin antagonists
US6344452B1 (en)	2002-02-05	1,5-benzodiazepine derivatives
US6747022B2 (en)	2004-06-08	Calcium salts of 1,5-benzodiazepine derivatives, process for producing the salts and drugs containing the same
JPH0680650A (ja)	1994-03-22	コレシストキニン拮抗薬
KR20020012567A (ko)	2002-02-16	1,5-벤조디아제핀 유도체
AU688316B2 (en)	1998-03-12	1,5 benzodiazepine derivatives having CCK and/or gastrin antagonistic activity
AU2004201385A1 (en)	2004-04-29	1,5-benzodiazepine derivatives
WO2010067233A1 (fr)	2010-06-17	1,2,4 triazolo[4,3-a][1,5] benzodiazépin-5(6h)-ones utilisées comme agonistes du récepteur de la cholécystokinine-1 (cck-1r)
JP2001512731A (ja)	2001-08-28	ＡＭＰＡ／Ｋａｉｎａｔｅ受容体阻害剤としての１，３−ジオキソロ／４，５−Ｈ／２，３／ベンゾジアゼピン誘導体
CH674008A5 (fr)	1990-04-30
ZA200108827B (en)	2003-01-27	1,5-Benzodiazepine derivatives as CCK-A receptor agonists.
HK1167144A (en)	2012-11-23	Amide derivatives as neuropeptide y5 receptor ligands

Legal Events

Date	Code	Title	Description
2001-11-05	PA0105	International application	Patent event date: 20011105 Patent event code: PA01051R01D Comment text: International Patent Application
2002-02-16	PG1501	Laying open of application
2005-05-05	PC1203	Withdrawal of no request for examination
2005-05-05	WITN	Application deemed withdrawn, e.g. because no request for examination was filed or no examination fee was paid